Colorectal cancer (CRC) represents the third most common malignancy throughout the world. Little or no improvement in survival has been effectively achieved in the last 50 years. Extensive epidemiological and genetic data are able to identify more precisely definite risk-groups so screening and early diagnosis can be more frequently accomplished. CRC is best detected by colonoscopy, which allows sampling for histologic diagnosis. Colonoscopy is the gold standard for detection of small and premalignant lesions, although it is not cost-effective for screening average-risk population. Colonoscopic polypectomy and mucosal resection constitute curative treatment for selective cases of invasive CRC. Similarly, alternative trans-colonoscopic treatment can be offered for adequate palliation, thus avoiding surgery. Colorectal cancer (CRC) represents the third most common malignancy worldwide 1 and the second leading cause of cancer-related death in the U.S., regardless of sex. In 1998, it is estimated that 20 000 cases were newly diagnosed, and 6000 Brazilians died of the disease 2 . Five-year associated mortality remains unchanged around 50% 3 ; advances in the operative technique and adjuvant therapy produced a modest impact on survival 4 . In this paper, a brief review of aspects of etiology, epidemiology, genetics, histology, and main determinants of prognosis of CRC will be followed by an in-depth evaluation of the role of colonoscopy in the screening, diagnosis, treatment, and surveillance of patients with CRC.